Health LT3001 Shows Promising Results for Stroke Patients in Trials Lumosa Therapeutics has announced encouraging findings from two Phase 2 clinical trials of its innovative stroke treatment, LT3001 (Odatroltide). The trials demonstrated significant functional... Editorial6 February, 2026